Deepa Pakianathan
Direktor/Vorstandsmitglied bei THERAVANCE BIOPHARMA, INC.
Vermögen: 433 382 $ am 30.04.2024
Profil
Deepa R.
Pakianathan currently works at Redd Pharmaceuticals, Inc., as Chief Executive Officer from 2019, San Francisco Conservatory of Music, as Executive Vice Chairman & Treasurer, Karyopharm Therapeutics, Inc., as Independent Director from 2013, Theravance Biopharma, Inc., as Independent Director from 2020, Mereo BioPharma Group Plc, as Independent Non-Executive Director from 2019, Palleon Pharmaceuticals, Inc., as Independent Director from 2020, Delphi Ventures III LP, as Managing Member, Delphi Ventures, Inc., as Managing Partner, Delphi Management Partners VII LLC, as Managing Member, and Delphi Management Partners VIII LLC, as Managing Member from 2013.
Dr. Pakianathan also formerly worked at Phenomix Corp., as Director from 2005 to 2010, PTC Therapeutics, Inc., as Director from 2009 to 2013, OncoMed Pharmaceuticals, Inc., as Independent Director from 2012 to 2019, Alexza Pharmaceuticals, Inc., as Independent Director from 2004 to 2016, Adiana, Inc., as Director, Antipodean Pharmaceuticals, Inc., as Director, Ilypsa, Inc., as Director, Proteolix, Inc., as Director, National Venture Capital Association, as Director, Lundbeck Seattle BioPharmaceuticals, Inc., as Independent Director from 2013 to 2019, NeurAxon, Inc., as Director, Relypsa, Inc., as Director from 2007 to 2012, FS Development Corp., as Independent Director, FS Development Corp.
II, as Independent Director, Calithera Biosciences, Inc., as Lead Independent Director, Genentech, Inc., as Postdoctoral Scientist from 1993 to 1997, J.P.
Morgan Partners LLC, as Senior Biotechnology Banker from 1998 to 2001, Genesis Merchant Group Securities LLC, as Research Analyst from 1997 to 1998, and J.P.
Morgan & Co. Ltd., as Vice President from 1998 to 2001.
Dr. Pakianathan received her graduate degree and doctorate degree from Wake Forest University, undergraduate degree and graduate degree from the University of Mumbai, and graduate degree from Advanced Centre for Treatment Research & Education in Cancer.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
THERAVANCE BIOPHARMA INC
0,10% | 08.05.2024 | 47 416 ( 0,10% ) | 433 382 $ | 30.04.2024 |
| 30.04.2023 | 0 ( -.--% ) | - $ | 31.03.2024 | |
| 29.03.2024 | 0 ( -.--% ) | - $ | 30.04.2024 | |
| 08.02.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Deepa Pakianathan
| Unternehmen | Position | Beginn |
|---|---|---|
| KARYOPHARM THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 01.04.2013 |
| MEREO BIOPHARMA GROUP PLC | Direktor/Vorstandsmitglied | 23.04.2019 |
| THERAVANCE BIOPHARMA, INC. | Direktor/Vorstandsmitglied | 01.07.2020 |
Delphi Ventures, Inc.
 Delphi Ventures, Inc. Investment ManagersFinance Delphi Ventures Inc (Delphi Ventures) is a venture capital firm founded in 1988 by James Bochnowski. The firm is headquartered in San Mateo, California. | Private Equity Investor | 01.06.2001 |
| San Francisco Conservatory of Music | Direktor/Vorstandsmitglied | - |
Palleon Pharmaceuticals, Inc.
 Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | Direktor/Vorstandsmitglied | 04.12.2020 |
| Delphi Ventures III LP | Corporate Officer/Principal | - |
| Delphi Management Partners VII LLC | Corporate Officer/Principal | - |
| Delphi Management Partners VIII LLC | Corporate Officer/Principal | - |
| ░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ehemalige bekannte Positionen von Deepa Pakianathan
| Unternehmen | Position | Ende |
|---|---|---|
| ░░░░░ ░░░░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Deepa Pakianathan
| Wake Forest University | Doctorate Degree |
| University of Mumbai | Graduate Degree |
| Advanced Centre for Treatment Research & Education in Cancer | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| PTC THERAPEUTICS, INC. | Health Technology |
| KARYOPHARM THERAPEUTICS INC. | Health Technology |
| CALITHERA BIOSCIENCES, INC. | Health Technology |
| THERAVANCE BIOPHARMA, INC. | Health Technology |
| MEREO BIOPHARMA GROUP PLC | Health Technology |
| Private Unternehmen | 23 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
| Delphi Ventures III LP | Finance |
Phenomix Corp.
 Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Health Technology |
OncoMed Pharmaceuticals, Inc.
 OncoMed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoMed Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on discovering and developing novel therapeutics for cancer's growth, resistance, recurrence and metastasis. The company was founded by Michael F. Clarke and Max Wicha in August 2004 and is headquartered in Redwood City, CA. | Health Technology |
Alexza Pharmaceuticals, Inc.
 Alexza Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexza Pharmaceuticals, Inc. is a pharmaceutical company. It focused on the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. Its product candidates are AZ-002 and AZ-007. The company was founded by Alejandro C. Zaffaroni in 2000 and is headquartered in Mountain View, CA. | Health Technology |
Adiana, Inc.
 Adiana, Inc. Medical SpecialtiesHealth Technology Adiana, Inc. develops contraceptive medical devices. It engages in the development and testing of transcervical sterilization system for permanent birth control. The company was founded by Peter Breining in July 1997 and is headquartered in Redwood City, CA. | Health Technology |
Antipodean Pharmaceuticals, Inc.
 Antipodean Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Antipodean Pharmaceuticals, Inc. manufactures pharmaceutical products and provides pre clinical services. Its product MitoQ, which blocks mitochondrial oxidative damage and prevents cell death. The company was founded in 2002 and is headquartered in Menlo Park, CA. | Health Technology |
J.P. Morgan Partners LLC
 J.P. Morgan Partners LLC Investment ManagersFinance J.P. Morgan Partners LLC is a private equity firm founded in 1984. The firm headquartered located in New York City. | Finance |
Genesis Merchant Group Securities LLC
 Genesis Merchant Group Securities LLC Investment Banks/BrokersFinance Part of JWGenesis Financial, Inc., Genesis Merchant Group Securities LLC provides security brokerage and dealer services. The company is based in Miami, FL. The company was founded by Barry S. Rosenstein. Genesis Merchant Group Securities was acquired by JWGenesis Financial, Inc. on June 12, 1998 for $15.95 million. | Finance |
| J.P. Morgan & Co. Ltd. | Finance |
Ilypsa, Inc.
 Ilypsa, Inc. BiotechnologyHealth Technology Ilypsa, Inc. operates a biopharmaceutical firm. It develops renal care pharmaceutical products. The company was founded on March 6, 2003 and is headquartered in Thousand Oaks, CA. | Health Technology |
Proteolix, Inc.
 Proteolix, Inc. Pharmaceuticals: MajorHealth Technology Proteolix, Inc. manufactures bio-pharmaceutical related products. It engages in the discovery, development, and marketing of pharmaceutical products to treat cancer and immunological conditions. The company was founded by Susan M. Molineauxf in December 2003 and is headquartered in South San Francisco, CA | Health Technology |
Delphi Ventures, Inc.
Delphi Ventures, Inc. Investment ManagersFinance Delphi Ventures Inc (Delphi Ventures) is a venture capital firm founded in 1988 by James Bochnowski. The firm is headquartered in San Mateo, California. | Finance |
National Venture Capital Association
 National Venture Capital Association Miscellaneous Commercial ServicesCommercial Services National Venture Capital Association provides business association services. It facilitates networking opportunities and provides research data to its members. The company is headquartered in Washington, DC. | Commercial Services |
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
| Delphi Management Partners VII LLC | |
NeurAxon, Inc.
 NeurAxon, Inc. Miscellaneous Commercial ServicesCommercial Services NeurAxon, Inc. is engaged in the research and development of growing and unmet needs for chronic pain management. It is focused on developing pain therapeutics targeting neuronal Nitric Oxide Synthase (nNOS) inhibitors. The companyw as founded in 2004 and is headquartered in Mississauga, ON. | Commercial Services |
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
| Delphi Management Partners VIII LLC | |
Palleon Pharmaceuticals, Inc.
Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | Commercial Services |
FS Development Corp.
 FS Development Corp. Financial ConglomeratesFinance FS Development Corp. operates as a blank check company. It is for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded by Jim Tananbaum in June 2020 and is headquartered in San Francisco, CA. | Finance |
FS Development Corp. II
 FS Development Corp. II Financial ConglomeratesFinance FS Development Corp. II is a blank check company, which formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more entities. The company was founded by James B. Tananbaum on August 21, 2020 and is headquartered in Larkspur, CA. | Finance |
| Redd Pharmaceuticals, Inc. |
